Do analysts rate JYNT or VMD?

Viemed Healthcare has a consensus target price of $14.00, indicating a potential upside of 47.06%. Given Viemed Healthcare's stronger consensus rating and higher possible upside, analysts clearly believe Viemed Healthcare is more favorable than Joint. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Joint 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 Viemed Healthcare 0 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.25

Which has stronger earnings and valuation, JYNT or VMD?

Viemed Healthcare has higher revenue and earnings than Joint. Joint is trading at a lower price-to-earnings ratio than Viemed Healthcare, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Joint $54.90M 1.81 $2.91M $0.27 26.07 Viemed Healthcare $270.28M 1.34 $14.93M $0.36 26.44

Does the media favor JYNT or VMD?

In the previous week, Joint had 1 more articles in the media than Viemed Healthcare. MarketBeat recorded 3 mentions for Joint and 2 mentions for Viemed Healthcare. Viemed Healthcare's average media sentiment score of 0.46 beat Joint's score of 0.45 indicating that Viemed Healthcare is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Joint 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Viemed Healthcare 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate TACO or JYNT?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Berto Acquisition 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Joint 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Which has stronger earnings & valuation, TACO or JYNT?

Joint has higher revenue and earnings than Berto Acquisition. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Berto Acquisition N/A N/A N/A N/A N/A Joint $54.90M 1.81 $2.91M $0.27 26.07

Do analysts prefer BDSX or JYNT?

Biodesix currently has a consensus price target of $35.00, suggesting a potential upside of 34.51%. Given Biodesix's stronger consensus rating and higher probable upside, equities analysts clearly believe Biodesix is more favorable than Joint. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biodesix 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.80 Joint 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Which has higher valuation & earnings, BDSX or JYNT?

Joint has lower revenue, but higher earnings than Biodesix. Biodesix is trading at a lower price-to-earnings ratio than Joint, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biodesix $88.50M 3.10 -$35.26M -$3.17 N/A Joint $54.90M 1.81 $2.91M $0.27 26.07

Is BDSX or JYNT more profitable?

Joint has a net margin of 6.49% compared to Biodesix's net margin of -26.97%. Joint's return on equity of 12.02% beat Biodesix's return on equity. Company Net Margins Return on Equity Return on Assets Biodesix -26.97% -788.19% -30.33% Joint 6.49% 12.02% 3.47%

Do analysts rate JYNT or INFU?

InfuSystem has a consensus price target of $17.50, indicating a potential upside of 29.06%. Given InfuSystem's stronger consensus rating and higher possible upside, analysts clearly believe InfuSystem is more favorable than Joint. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Joint 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 InfuSystem 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00

Which has preferable valuation and earnings, JYNT or INFU?

Joint has higher earnings, but lower revenue than InfuSystem. Joint is trading at a lower price-to-earnings ratio than InfuSystem, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Joint $54.90M 1.81 $2.91M $0.27 26.07 InfuSystem $143.34M 1.91 $870K $0.41 33.07

Is JYNT or INFU more profitable?

Joint has a net margin of 6.49% compared to InfuSystem's net margin of 1.12%. Joint's return on equity of 12.02% beat InfuSystem's return on equity. Company Net Margins Return on Equity Return on Assets Joint 6.49% 12.02% 3.47% InfuSystem 1.12% 2.78% 1.41%

Do analysts rate JYNT or XGN?

Exagen has a consensus price target of $9.63, suggesting a potential upside of 14.31%. Given Exagen's stronger consensus rating and higher possible upside, analysts clearly believe Exagen is more favorable than Joint. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Joint 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 Exagen 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.89

Which has stronger earnings and valuation, JYNT or XGN?

Joint has higher earnings, but lower revenue than Exagen. Exagen is trading at a lower price-to-earnings ratio than Joint, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Joint $54.90M 1.81 $2.91M $0.27 26.07 Exagen $66.57M 3.06 -$19.95M -$0.81 N/A

Is JYNT or XGN more profitable?

Joint has a net margin of 6.49% compared to Exagen's net margin of -26.61%. Joint's return on equity of 12.02% beat Exagen's return on equity. Company Net Margins Return on Equity Return on Assets Joint 6.49% 12.02% 3.47% Exagen -26.61% -104.46% -28.93%

Joint (JYNT) Competitors

$7.04 -0.08 (-1.12%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$7.02 -0.02 (-0.28%)

As of 10/9/2026 07:30 PM Eastern

Compare

JYNT vs. VMD, TACO, BDSX, INFU, and XGN

Should you buy Joint stock or one of its competitors? Joint's main competitors and comparable companies include Viemed Healthcare (VMD), Berto Acquisition (TACO), Biodesix (BDSX), InfuSystem (INFU), and Exagen (XGN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare services" industry.

How does Joint compare to Viemed Healthcare?

Joint (NASDAQ:JYNT) and Viemed Healthcare (NASDAQ:VMD) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, dividends, valuation, analyst recommendations, institutional ownership, risk and profitability.

Joint has a beta of 1.09, indicating that its stock price is 9% more volatile than the broader market. Comparatively, Viemed Healthcare has a beta of 1.04, indicating that its stock price is 4% more volatile than the broader market.

Viemed Healthcare has higher revenue and earnings than Joint. Joint is trading at a lower price-to-earnings ratio than Viemed Healthcare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Joint	$54.90M	1.81	$2.91M	$0.27	26.07
Viemed Healthcare	$270.28M	1.34	$14.93M	$0.36	26.44

76.9% of Joint shares are owned by institutional investors. Comparatively, 74.2% of Viemed Healthcare shares are owned by institutional investors. 30.2% of Joint shares are owned by company insiders. Comparatively, 20.6% of Viemed Healthcare shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Joint had 1 more articles in the media than Viemed Healthcare. MarketBeat recorded 3 mentions for Joint and 2 mentions for Viemed Healthcare. Viemed Healthcare's average media sentiment score of 0.46 beat Joint's score of 0.45 indicating that Viemed Healthcare is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Joint	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Viemed Healthcare	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Joint has a net margin of 6.49% compared to Viemed Healthcare's net margin of 4.81%. Joint's return on equity of 12.02% beat Viemed Healthcare's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Joint	6.49%	12.02%	3.47%
Viemed Healthcare	4.81%	10.16%	7.22%

Viemed Healthcare has a consensus target price of $14.00, indicating a potential upside of 47.06%. Given Viemed Healthcare's stronger consensus rating and higher possible upside, analysts clearly believe Viemed Healthcare is more favorable than Joint.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Joint	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Viemed Healthcare	0 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Viemed Healthcare beats Joint on 9 of the 16 factors compared between the two stocks.

How does Joint compare to Berto Acquisition?

Berto Acquisition (NASDAQ:TACO) and Joint (NASDAQ:JYNT) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, risk, earnings, profitability, analyst recommendations, dividends, valuation and media sentiment.

In the previous week, Joint had 1 more articles in the media than Berto Acquisition. MarketBeat recorded 3 mentions for Joint and 2 mentions for Berto Acquisition. Berto Acquisition's average media sentiment score of 1.39 beat Joint's score of 0.45 indicating that Berto Acquisition is being referred to more favorably in the media.

Company	Overall Sentiment
Berto Acquisition	Positive
Joint	Neutral

Berto Acquisition has a beta of 0.08, suggesting that its stock price is 92% less volatile than the broader market. Comparatively, Joint has a beta of 1.09, suggesting that its stock price is 9% more volatile than the broader market.

Joint has a net margin of 6.49% compared to Berto Acquisition's net margin of 0.00%. Joint's return on equity of 12.02% beat Berto Acquisition's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Berto Acquisition	N/A	N/A	N/A
Joint	6.49%	12.02%	3.47%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Berto Acquisition	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Joint	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

76.9% of Joint shares are owned by institutional investors. 13.2% of Berto Acquisition shares are owned by company insiders. Comparatively, 30.2% of Joint shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Joint has higher revenue and earnings than Berto Acquisition.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Berto Acquisition	N/A	N/A	N/A	N/A	N/A
Joint	$54.90M	1.81	$2.91M	$0.27	26.07

Summary

Joint beats Berto Acquisition on 9 of the 10 factors compared between the two stocks.

How does Joint compare to Biodesix?

Biodesix (NASDAQ:BDSX) and Joint (NASDAQ:JYNT) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, media sentiment, risk, valuation and earnings.

Joint has a net margin of 6.49% compared to Biodesix's net margin of -26.97%. Joint's return on equity of 12.02% beat Biodesix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biodesix	-26.97%	-788.19%	-30.33%
Joint	6.49%	12.02%	3.47%

Biodesix has a beta of 0.56, suggesting that its stock price is 44% less volatile than the broader market. Comparatively, Joint has a beta of 1.09, suggesting that its stock price is 9% more volatile than the broader market.

Biodesix currently has a consensus price target of $35.00, suggesting a potential upside of 34.51%. Given Biodesix's stronger consensus rating and higher probable upside, equities analysts clearly believe Biodesix is more favorable than Joint.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biodesix	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Joint	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Joint has lower revenue, but higher earnings than Biodesix. Biodesix is trading at a lower price-to-earnings ratio than Joint, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biodesix	$88.50M	3.10	-$35.26M	-$3.17	N/A
Joint	$54.90M	1.81	$2.91M	$0.27	26.07

In the previous week, Joint had 2 more articles in the media than Biodesix. MarketBeat recorded 3 mentions for Joint and 1 mentions for Biodesix. Biodesix's average media sentiment score of 1.79 beat Joint's score of 0.45 indicating that Biodesix is being referred to more favorably in the media.

Company	Overall Sentiment
Biodesix	Very Positive
Joint	Neutral

21.0% of Biodesix shares are owned by institutional investors. Comparatively, 76.9% of Joint shares are owned by institutional investors. 23.2% of Biodesix shares are owned by company insiders. Comparatively, 30.2% of Joint shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Joint beats Biodesix on 10 of the 17 factors compared between the two stocks.

How does Joint compare to InfuSystem?

Joint (NASDAQ:JYNT) and InfuSystem (NYSE:INFU) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, dividends, institutional ownership, analyst recommendations, earnings and valuation.

InfuSystem has a consensus price target of $17.50, indicating a potential upside of 29.06%. Given InfuSystem's stronger consensus rating and higher possible upside, analysts clearly believe InfuSystem is more favorable than Joint.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Joint	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
InfuSystem	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

76.9% of Joint shares are held by institutional investors. Comparatively, 71.1% of InfuSystem shares are held by institutional investors. 30.2% of Joint shares are held by insiders. Comparatively, 10.8% of InfuSystem shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Joint has a beta of 1.09, indicating that its stock price is 9% more volatile than the broader market. Comparatively, InfuSystem has a beta of 1.49, indicating that its stock price is 49% more volatile than the broader market.

In the previous week, Joint had 3 more articles in the media than InfuSystem. MarketBeat recorded 3 mentions for Joint and 0 mentions for InfuSystem. Joint's average media sentiment score of 0.45 beat InfuSystem's score of 0.00 indicating that Joint is being referred to more favorably in the media.

Company	Overall Sentiment
Joint	Neutral
InfuSystem	Neutral

Joint has a net margin of 6.49% compared to InfuSystem's net margin of 1.12%. Joint's return on equity of 12.02% beat InfuSystem's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Joint	6.49%	12.02%	3.47%
InfuSystem	1.12%	2.78%	1.41%

Joint has higher earnings, but lower revenue than InfuSystem. Joint is trading at a lower price-to-earnings ratio than InfuSystem, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Joint	$54.90M	1.81	$2.91M	$0.27	26.07
InfuSystem	$143.34M	1.91	$870K	$0.41	33.07

Summary

Joint and InfuSystem tied by winning 8 of the 16 factors compared between the two stocks.

How does Joint compare to Exagen?

Joint (NASDAQ:JYNT) and Exagen (NASDAQ:XGN) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, media sentiment, dividends, earnings and risk.

Joint has higher earnings, but lower revenue than Exagen. Exagen is trading at a lower price-to-earnings ratio than Joint, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Joint	$54.90M	1.81	$2.91M	$0.27	26.07
Exagen	$66.57M	3.06	-$19.95M	-$0.81	N/A

76.9% of Joint shares are owned by institutional investors. Comparatively, 75.3% of Exagen shares are owned by institutional investors. 30.2% of Joint shares are owned by insiders. Comparatively, 10.4% of Exagen shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Joint has a net margin of 6.49% compared to Exagen's net margin of -26.61%. Joint's return on equity of 12.02% beat Exagen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Joint	6.49%	12.02%	3.47%
Exagen	-26.61%	-104.46%	-28.93%

Exagen has a consensus price target of $9.63, suggesting a potential upside of 14.31%. Given Exagen's stronger consensus rating and higher possible upside, analysts clearly believe Exagen is more favorable than Joint.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Joint	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Exagen	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

Joint has a beta of 1.09, indicating that its share price is 9% more volatile than the broader market. Comparatively, Exagen has a beta of 2.12, indicating that its share price is 112% more volatile than the broader market.

In the previous week, Joint had 2 more articles in the media than Exagen. MarketBeat recorded 3 mentions for Joint and 1 mentions for Exagen. Exagen's average media sentiment score of 1.52 beat Joint's score of 0.45 indicating that Exagen is being referred to more favorably in the news media.

Company	Overall Sentiment
Joint	Neutral
Exagen	Very Positive

Summary

Joint beats Exagen on 9 of the 17 factors compared between the two stocks.

Get Joint News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding JYNT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

JYNT vs. The Competition

Export

Metric	Joint	Healthcare Providers & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$99.57M	$9.94B	$7.25B	$13.30B
Dividend Yield	N/A	2.61%	2.52%	22.58%
P/E Ratio	26.07	34.10	275.01	26.14
Price / Sales	1.81	4.83	582.85	87.88
Price / Cash	72.38	114.01	76.96	53.71
Price / Book	6.97	5.11	11.22	6.33
Net Income	$2.91M	$315.68M	$3.50B	$382.15M
7 Day Performance	-3.30%	-0.38%	-0.89%	-1.40%
1 Month Performance	-10.32%	-2.14%	-4.02%	-3.35%
1 Year Performance	-12.66%	12.73%	7.13%	1.49%

Joint Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
JYNT Joint	2.1605 of 5 stars	$7.04 -1.1%	N/A	-12.7%	$99.57M	$54.90M	26.07	330
VMD Viemed Healthcare	3.8451 of 5 stars	$9.33 +1.0%	$14.00 +50.1%	+39.6%	$355.36M	$301.61M	25.92	1,382	News Coverage
TACO Berto Acquisition	1.4483 of 5 stars	$10.46 flat	N/A	+0.3%	$341.21M	N/A	N/A	7,892	Short Interest Decrease
BDSX Biodesix	4.475 of 5 stars	$27.96 -3.8%	$35.00 +25.2%	+255.5%	$295.01M	$102.94M	N/A	334	Positive News
INFU InfuSystem	3.2344 of 5 stars	$13.27 -1.6%	$17.50 +31.9%	+46.9%	$267.82M	$143.34M	221.20	473

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:JYNT) was last updated on 10/11/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Joint (JYNT) Competitors

JYNT vs. VMD, TACO, BDSX, INFU, and XGN

How does Joint compare to Viemed Healthcare?

Summary

How does Joint compare to Berto Acquisition?

Summary

How does Joint compare to Biodesix?

Summary

How does Joint compare to InfuSystem?

Summary

How does Joint compare to Exagen?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

JYNT vs. The Competition

Joint Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Joint (JYNT) Competitors

JYNT vs. VMD, TACO, BDSX, INFU, and XGN

How does Joint compare to Viemed Healthcare?

Which has more risk and volatility, JYNT or VMD?

Which has stronger earnings and valuation, JYNT or VMD?

Do insiders & institutionals hold more shares of JYNT or VMD?

Does the media favor JYNT or VMD?

Is JYNT or VMD more profitable?

Do analysts rate JYNT or VMD?

Summary

How does Joint compare to Berto Acquisition?

Does the media prefer TACO or JYNT?

Which has more volatility & risk, TACO or JYNT?

Is TACO or JYNT more profitable?

Do analysts rate TACO or JYNT?

Do insiders & institutionals hold more shares of TACO or JYNT?

Which has stronger earnings & valuation, TACO or JYNT?

Summary

How does Joint compare to Biodesix?

Is BDSX or JYNT more profitable?

Which has more volatility & risk, BDSX or JYNT?

Do analysts prefer BDSX or JYNT?

Which has higher valuation & earnings, BDSX or JYNT?

Does the media refer more to BDSX or JYNT?

Do institutionals & insiders have more ownership in BDSX or JYNT?

Summary

How does Joint compare to InfuSystem?

Do analysts rate JYNT or INFU?

Do insiders and institutionals believe in JYNT or INFU?

Which has more risk & volatility, JYNT or INFU?

Does the media favor JYNT or INFU?

Is JYNT or INFU more profitable?

Which has preferable valuation and earnings, JYNT or INFU?

Summary

How does Joint compare to Exagen?

Which has stronger earnings and valuation, JYNT or XGN?

Do institutionals and insiders hold more shares of JYNT or XGN?

Is JYNT or XGN more profitable?

Do analysts rate JYNT or XGN?

Which has more risk and volatility, JYNT or XGN?

Does the media favor JYNT or XGN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

JYNT vs. The Competition

Joint Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools